NASDAQ: VRCA - Verrica Pharmaceuticals Inc.

六个月盈利: -90.84%
部门: Healthcare

促销时间表 Verrica Pharmaceuticals Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

更多详情
It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2018-06-15
ISIN US92511W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.verrica.com
Цена ао 5.32
每日价格变化: +5.39% (0.649)
每周价格变化: -1.44% (0.694)
每月价格变化: -44.84% (1.24)
3个月内价格变化: -59.53% (1.69)
六个月内的价格变化: -90.84% (7.47)
每年价格变化: -90.66% (7.32)
3年内价格变化: -92.58% (9.22)
5年内价格变化: -95.78% (16.2)
10年价格变化: 0% (0.684)
年初以来价格变化: -44.84% (1.24)
所有参数

低估

姓名 意义 年级
P/S 57.52 1
P/BV 14.91 1
P/E 0 0
EV/EBITDA -4.34 0
全部的: 2.75

效率

姓名 意义 年级
ROA, % -82.1 0
ROE, % -338.99 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.6985 10
全部的: 7.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -57.3 0
盈利能力 Ebitda, % 106.63 10
盈利能力 EPS, % 40.72 6
全部的: 6.2
更多详情

机构 体积 分享, %
Perceptive Advisors LLC 5038983 11.98
Avoro Capital Advisors LLC 2954064 7.02
FMR, LLC 1504716 3.58
Vanguard Group Inc 1226858 2.92
Blackrock Inc. 1051050 2.5
Geode Capital Management, LLC 416790 0.99
State Street Corporation 382743 0.91
Caligan Partners, LP 259593 0.62
Northern Trust Corporation 187478 0.45
Boxer Capital, LLC 166955 0.4

ETF 分享, % 本年盈利能力, % 股息, %
Invesco Dorsey Wright SmallCap Momentum ETF 0.07518 33.91 0.61241
iShares Micro-Cap ETF 0.00867 17.09 1.54048
iShares Russell 2000 Growth ETF 0.0017 38.04 0.6026
ProShares UltraPro Russell2000 0.00074 89.82 1.47873
ProShares Hedge Replication ETF 0.00022 5.92 1.47892
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



导师 职称 支付 出生年份
Mr. Ted White President, CEO & Director 772.77k 1965 (60 年)
Dr. Gary Goldenberg M.D. Chief Medical Officer 553.03k 1977 (48 年)
Mr. P. Terence Kohler Chief Financial Officer N/A
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel N/A 1964 (61 年)
Mr. Eugene Scavola Executive Vice President of Technical Operations N/A
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development N/A

地址: United States, West Chester. PA, 44 West Gay Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.verrica.com